• Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells 

      Wenger, Anna; Werlenius, Katja; Hallner, Alexander; Fredrik Bergh, Thoren; Farahmand, Dan; Tisell, Magnus; Smits, Anja; Rydenhag, Bertil; Jakola, Asgeir Store; Caren, Helena (Peer reviewed; Journal article, 2018)
      Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of less than 15 months, emphasizing the need for better treatments. Immunotherapy as a treatment for improving or aiding the patient’s ...
    • Neurosurgical treatment and outcome patterns of meningioma in Sweden: a nationwide registry-based study 

      Corell, Alba; Thurin, Erik; Skoglund, Thomas; Farahmand, Dan; Henriksson, Roger; Rydenhag, Bertil; Gulati, Sasha; Bártek, Jiří; Jakola, Asgeir Store (Peer reviewed; Journal article, 2019)
      Background Surgery is the main treatment modality for intracranial meningiomas, but data on short-term surgical outcome are limited. The aim of this Swedish nationwide registry-based study was to benchmark the 30-day ...